Quality Segment
assay
≥95% (SDS-PAGE)
form
liquid
specific activity
≥2000 C5b,6H50 units/mg
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, avoid repeated freeze/thaw cycles
shipped in
wet ice
storage temp.
−70°C
General description
Native, human C5b,6 complement component complex. Activation of complement by either pathway results in the formation of C5-cleaving enzymes (C5 convertases) on target surfaces. The C5 convertase enzymes cleave the C5 α-chain at peptide bond 74, resulting in the formation of the C5a anaphylatoxin (M.W. 11,200) and the C5b fragment (M.W. 185,000). The nascent C5b fragment can combine with C6, C7, C8, and C9 to form the lytic C5b-9 membrane attack complex on target surfaces. When C5 activation occurs in the presence of C6 only, e.g. in C7 deficient serum, a stable C5b,6 complex is formed. In a process termed Reactive Lysis, the membrane attack complex can be assembled on target cell surfaces in the absence of any additional complement proteins by incubating target cells with the C5b,6 complex and purified C7, C8, and C9.
Packaging
Please refer to vial label for lot-specific concentration.
Other Notes
Podack, E.R., et al. 1978. J. Immunol. 120, 1841.
Lachmann, P.J. and Thompson, R.A. 1970. J. Exp. Med. 131, 643.
Lachmann, P.J. and Thompson, R.A. 1970. J. Exp. Med. 131, 643.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
保管分類
12 - Non Combustible Liquids
wgk
nwg
試験成績書(COA)
製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。